ERBB2 and breast carcinoma: Recently, a novel biomimetic platform exploiting a combination of chimeric antigen receptor-natural killer (CAR-NK) cell-derived exosomes (ExoCAR), and a Micelle nano bomb named ExoCAR/T7@Micelle was tested, successfully crossed the blood–brain barrier and selectively targeted HER2+ breast cancer cell brain metastases releasing cargo at desired sites leading to a robust antitumor response in vivo, with a significant extension in survival time, without any side effects [95].